2025³â 06¿ù 24ÀÏ È­¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Science & Technology

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýȰ

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óǰ

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

Center for Disease Analysis Foundation Receives $7 Million Grant from the John C. Martin Foundation to Support the Polaris Observatory

´º½ºÀÏÀÚ: 2024-11-22

LAFAYETTE, COLO. -- The Center for Disease Analysis (CDA) Foundation announced receipt of a $7 million grant from the John C. Martin Foundation to sustain and expand the Polaris Observatory until the end of 2030.

The Polaris Observatory serves as the definitive source for global data on hepatitis B and C virus (HBV and HCV) burden, providing insights into the prevalence and distribution of these viruses across countries, regions, and globally. It also assists national governments and international organizations in monitoring progress toward the World Health Organization’s (WHO) 2030 elimination targets for HBV and HCV. Annually, the Observatory collaborates with over 1,000 national experts in 120 countries, updating forecasts for each country. Additionally, it offers pro bono support to national governments, assisting them in developing and implementing elimination programs and strategies to fund for their initiatives.

“We are deeply grateful for the John C. Martin Foundation’s unwavering support,” expressed Homie Razavi, Managing Director of the CDA Foundation. “Their initial funding in 2015 catalyzed the establishment of the Polaris Observatory, and their continuous support has enabled us to sustain our work. The Observatory’s programs are supported by a dedicated team of epidemiologists, mathematical modelers, programmers, and decision analysts. The Observatory’s contributions have resulted in nationally funded access to hepatitis screening for 1.7 billion people globally, laboratory testing (24 million people), and treatment (19 million people) as result of recognized value of early detection and treatment. This new grant will facilitate our continued efforts through 2030.”

“On behalf of the John C. Martin Foundation, it is a privilege to support the CDA Foundation in the past decade to service the international hepatitis elimination collaborators. We are grateful for the opportunity to support such an impactful and momentous program,” said Dr. Lillian Lou, President, Program Director of the John C. Martin Foundation (https://thejcmfoundation.org).

CDA Foundation is a nonprofit organization focused on accelerating hepatitis B and C elimination through verified epidemiological data, disease burden and economic impact modeling, intervention strategies, innovative financing, and knowledge-sharing partnerships. It accomplishes these goals through the Polaris Observatory (https://cdafound.org/polaris/).



 Àüü´º½º¸ñ·ÏÀ¸·Î

QpiAI Announces Dawn of Quantum Era in India With 25 Qubit Quantum Computer
VeriSilicon¡¯s Scalable High-Performance GPGPU-AI Computing IPs Empower Automotive and Edge Server AI Solutions
Sky Labs Pioneers Future of Cuffless Blood Pressure Monitoring
LG Unveils World¡¯s First Thunderbolt 5 5K2K Monitor, Optimized for the Finance and IT Sectors
New Study Finds Masimo SedLine¢ç Brain Function Monitoring Offers Significant Advantages During Pediatric Anesthesia
HOYA Vision Care Unveils Updates from the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
VeriSilicon¡¯s AI-ISP Custom Chip Solution Enables Mass Production of Customer¡¯s Smartphones

 

ExaGrid Wins 2 New Industry Awards at the Storage Awards
Merck Presents Results on Efficacy and Safety of Enpatoran in Systemic...
SmartStream Brings AI-Powered Data Management to the Insurance Sector
Stellar Cyber Positioned in the Challenger Quadrant of the Gartner Mag...
KIOXIA and Linus Media Group Set World Record for Pi Calculation
China's Center for Drug Evaluation accepts Merck's application for Pim...
Capvidia Expands Model-Based Definition (MBD) Interoperability with QI...

 


°øÁö»çÇ×
´º½ºÁö ÇÑÀÚ Ç¥±â¿¡ ´ë¸¸½Ä À½Â÷ Ç¥±â '纽ÞÙó¢ ´Ï¿ì½ÃÁö' º´±â
º£³×ÇÁ·Ò º£³×ÀÎÅõ Áß¹® Ç¥±â 宝Ò¬ÜØÙÌ 宝Ò¬ì×öõ(ÜÄÒ¬ÜØÙÌ ÜÄ...
¹Ìµð¾î¾Æ¿ì¾î Mediaour ØÚ体ä²们 ØÚô÷ä²Ùú MO ¿¥¿À ØÚä² ØÚä²
¾Ë¸®¿ìºê Alliuv ä¹备: ä¹联êó备, ¾Ë¶ã Althle ä¹÷åìÌ
¾Ë¸®¾Ë Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øÃ¼ Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º : À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¹ÙÀÌ¿ÀÀÌ´Ï Bioini Áß¹® Ç¥±â ù±药研 ù±å·æÚ
¿À½ºÇÁ·Ò Ausfrom 奥ÞÙÜØÙÌ, À£ÇÁ·Ò Welfrom 卫ÜØÙÌ
¿¡³ÊÇÁ·Ò Enerfrom 额ÒöÜØÙÌ ¿¡³ÊÀ¯ºñ Eneruv 额Òöêó备
¾ËÇÁ·Ò Alfrom Áß¹® Ç¥±â ä¹尔ÜØÙÌ ä¹ì³ÜØÙÌ

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇѰè¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, ÆÑ½º 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..